
MSD to launch Keytruda at half US list price in China
pharmafile | September 20, 2018 | News story | Business Services, Sales and Marketing | BMS, China, MSD, global, keytruda, markets, pricing
US pharma giant MSD will offer cutting edge cancer treatment Keytruda to Chinese patients at half the price at what it is sold for in the United States, according to the Beijing-based news organisation Caixin Global.
Keytruda, which was approved in China in July of this year, will cost 17,918 yuan (£1,981) for a 100mg/ 4ml dose when it is introduced to the world’s second largest pharmaceutical market later this year.
The reduced price thus marks the lowest price at which Keytruda is sold around the world, at 50% of the US price and 30% lower than that of neighbouring Hong Kong.
The move comes after BristolMyersSquibb cut the price of cancer treatment Opdivo after it was authorised by the China Food and Drug Administration in June for patients with locally advanced or metastatic non-small-cell lung cancer. The therapy, which became the first PD-1 inhibitor approved in China, comes with a list price of 9260 yuan (£1023).
MSD have also announced that they have developed a patient financial assistance program for Keytruda, which will increase access for the humanised antibody which is used in cancer immunotherapy.
Louis Goss
Related Content

CARBOGEN AMCIS manufacturing license advances services in China
Swiss pharma manufacturing company, CARBOGEN AMCIS, has announced that its facility in Shanghai, China, has …

NDA in China receives priority review status for lung cancer treatment
HUTCHMED have announced that the China National Medical Products Administration (NMPA) have granted a priority …

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …






